Effect of inducible FHIT and p53 expression in the Calu-1 lung cancer cell line

Cancer Letters

Volumn 246, Issue 1-2, 2007, Pages 69-81

  Cavazzoni, A ^a   Galetti, M ^a   Fumarola, C ^a   Alfieri, R R ^a   Roz, L ^b   Andriani, F ^b   Carbognani, P ^a   Rusca, M ^a   Sozzi, G ^b   Petronini, P G ^a  

^a UNIVERSITY OF PARMA   (Italy)

^b NATIONAL CANCER INSTITUTE   (Italy)

Author keywords

FHIT; Inducible expression system; Lung cancer; p21; p53

Indexed keywords

CYCLIN DEPENDENT KINASE INHIBITOR 1; FRAGILE HISTIDINE TRIAD PROTEIN; MESSENGER RNA; PROTEIN MDM2; PROTEIN P53;

ARTICLE; CANCER CELL CULTURE; CANCER GENETICS; CELL PROLIFERATION; CONTROLLED STUDY; FHIT GENE; GENE; GENE EXPRESSION SYSTEM; HUMAN; HUMAN CELL; LUNG CANCER; LUNG CARCINOGENESIS; PRIORITY JOURNAL; PROTEIN DETERMINATION; PROTEIN EXPRESSION; PROTEIN INDUCTION;

ACID ANHYDRIDE HYDROLASES; APOPTOSIS; BLOTTING, NORTHERN; BLOTTING, WESTERN; CELL LINE, TUMOR; CELL PROLIFERATION; CYCLIN-DEPENDENT KINASE INHIBITOR P21; GENE EXPRESSION REGULATION, NEOPLASTIC; GENETIC VECTORS; HUMANS; NEOPLASM PROTEINS; PROTO-ONCOGENE PROTEINS C-MDM2; TIME FACTORS; TRANSFECTION; TUMOR SUPPRESSOR PROTEIN P53;

EID: 33845672652     PISSN: 03043835     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.canlet.2006.01.033     Document Type: Article

References (26)

1. Sozzi G., Veronese M.L., Negrini M., Baffa R., Cotticelli M.G., Inoue H., et al. The FHIT gene 3p14.2 is abnormal in lung cancer. Cell 85 (1996) 17-26
2. Sozzi G., Pastorino U., Moiraghi L., Tagliabue E., Pezzella F., Ghirelli C., et al. Loss of FHIT function in lung cancer and preinvasive bronchial lesions. Cancer Res. 58 (1998) 5032-5037
3. Rohr U.P., Rehfeld N., Geddert H., Pflugfelder L., Bruns I., Neukirch J., et al. Prognostic relevance of fragile histidine triad protein expression in patients with small cell lung cancer. Clin. Cancer Res. 11 (2005) 180-185
4. Toledo G., Sola J.J., Lozano M.D., Soria E., and Pardo J.G. Loss of FHIT protein expression is related to high proliferation, low apoptosis and worse prognosis in non-small-cell lung cancer. Mod. Pathol. 17 (2004) 440-448
5. Barnes L.D., Garrison P.N., Siprashvili Z., Guranowski A., Robinson A.K., Ingram S.W., et al. FHIT a putative tumor suppressor in humans, is a dinucleoside 5′,5‴-P1,P3-triphosphate hydrolase. Biochemistry 35 (1996) 11529-11535
6. Sard L., Accornero P., Tornielli S., Delia D., Bunone G., Campiglio M., et al. The tumor-suppressor gene FHIT is involved in the regulation of apoptosis and in cell cycle control. Proc. Natl Acad. Sci. USA 96 (1999) 8489-8492
7. Ji L., Fang B., Yen N., Fong K., Minna J.D., and Roth J.A. Induction of apoptosis and inhibition of tumorigenicity and tumor growth by adenovirus vector-mediated fragile histidine triad (FHIT) gene overexpression. Cancer Res. 59 (1999) 3333-3339
8. Roz L., Gramegna M., Ishii H., Croce C.M., and Sozzi G. Restoration of fragile histidine triad (FHIT) expression induces apoptosis and suppresses tumorigenicity in lung and cervical cancer cell lines. Proc. Natl Acad. Sci. USA 99 (2002) 3615-3620
9. Fong L.Y.Y., Fidanza V., Zanesi N., Lock L.F., Siracusa L.D., Mancini R., et al. Muir-Torre-like syndrome in FHIT-deficient mice. Proc. Natl Acad. Sci. USA 97 (2000) 4742-4747
10. Dumon K.R., Ishii H., Fong L.Y.Y., Zanesi N., Fidanza V., Mancini R., et al. FHIT gene therapy prevents tumor development in FHIT-deficient mice. Proc. Natl Acad. Sci. USA 98 (2001) 3346-3351
11. Cavazzoni A., Petronini P.G., Galetti M., Roz L., Andriani F., Carbognani P., et al. Dose-dependent effect of FHIT-inducible expression in Calu-1 lung cancer cell line. Oncogene 23 (2004) 8439-8446
12. Sevignani C., Calin G.A., Cesari R., Sarti M., Ishii H., Yendamuri S., et al. Restoration of fragile histidine triad (FHIT) expression induces apoptosis and suppresses tumorigenicity in breast cancer cell lines. Cancer Res. 63 (2003) 1183-1187
13. Ramesh R., Saeki T., Templeton N.S., Ji L., Stephens L.C., Ito I., et al. Successful treatment of primary and disseminated human lung cancers by systemic delivery of tumor suppressor genes using an improved liposome vector. Mol. Ther. 3 (2001) 337-350
14. Galmarini C.M., Kamath K., Vanier-Viornery A., Hervieu V., Peiller E., Falette N., et al. Drug resistance associated with loss of p53 involves extensive alterations in microtubule composition and dynamics. Br. J. Cancer 88 (2003) 1793-1799
15. Nishizaki M., Sasaki J., Fang B., Atkinson E.N., Minna J.D., Roth J.A., et al. Synergistic tumor suppression by coexpression of FHIT and p53 coincides with FHIT-mediated MDM2 inactivation and p53 stabilization in human non-small cell lung cancer cells. Cancer Res. 64 2004 (2004) 5745-5752
16. Fumarola C., Zerbini A., and Guidotti G.G. Glutamine deprivation-mediated cell shrinkage induces ligand-independent CD95 receptor signaling and apoptosis. Cell Death Differ. 8 (2001) 1004-1013
17. Petronini P.G., Alfieri R., De Angelis E., Campanini C., Borghetti A.F., and Wheeler K.P. Different HSP70 expression and cell survival during adaptive responses of 3T3 and transformed 3T3 cells to osmotic stress. Br. J. Cancer 67 (1993) 493-499
18. Mitsuuchi Y., and Testa J.R. Cytogenetics and molecular genetics of lung cancer. Am. J. Med. Genet. 115 (2002) 183-188
19. Garinis G.A., Gorgoulis V.G., Mariatos G., Zacharatos P., Kotsinas A., Liloglou T., et al. Association of allelic loss at the FHIT locus and p53 alterations with tumour kinetics and chromosomal instability in non-small cell lung carcinomas (NSCLCs). J. Pathol. 193 (2001) 55-65
20. Chang Y., Wu C.T., Shih J.Y., and Lee Y.C. Roles of FHIT and p53 in Taiwanese surgically treated non-small-cell lung cancers. Br. J. Cancer 89 (2003) 320-326
21. Mascaux C., Martin B., Verdebout J.M., Meert A.P., Ninane V., and Sculier J.P. Fragile histidine triad protein expression in non small cell lung cancer and correlation with Ki-67 and with p53. Eur. Respir. J. 21 (2003) 753-758
22. Lee Y.C., Wu C.T., Shih J.Y., Jou Y.S., and Chang Y.L. Frequent allelic deletion at the FHIT locus associated with p53 overexpression in squamous cell carcinoma subtype of Taiwanese non-small-cell lung cancers. Br. J. Cancer 90 (2004) 2378-2383
23. Fridman J.S., and Lowe S.W. Control of apoptosis by p53. Oncogene 22 (2003) 9030-9040
24. David W. Meek and Uwe Knippschild, Posttranslational modification of MDM2. Mol. Cancer Res. 1 (2003) 1017-1026
25. Weng M.W., Lai J.C., Hsu C.P., Yu K.Y., Chen C.Y., Lin T.S., et al. Alternative splicing of MDM2 mRNA in lung carcinomas and lung cell lines. Environ. Mol. Mutagen. 46 (2005) 1-11
26. Sandig V., Brand K., Herwig S., Lukas J., Bartek J., and Strauss M. Adenovirally transferred p16INK4/CDKN2 and p53 genes cooperate to induce apoptotic tumor cell death. Nat. Med. 3 (1997) 313-319